Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study

Table 2

Nasal nitric oxide levels and responses to items on the impact of Sinonasal Outcomes Test-20 (SNOT-20) questionnaire.

Characteristics or outcome	HIV+ with suppressed VL on ART; ()	HIV+ with detectable VL off ART; ()	Healthy Controls; ()
Nasal nitric oxide levels (nL/min) [mean (std)]^#	253 (77)	213 (48)	289 (68)	0.133
Nasal nitric oxide levels (nl/min) [median (IQR)]	251 (200, 311)	200 (172, 259)	274 (233, 330)
Range in nitric oxide levels (nL/min)	116–421	147–264	197–432
Participants with levels ≤300 nL/min,	29 (71%)	5 (100%)	7 (58%)	0.291
Total points on the SNOT-20 questionnaire (100 possible) [mean (std)]^#	19 (16)	18 (26)	4 (4)	0.013
Participants with total points 0– (no problem to mild problem) [ (%)]	19 (46%)	3 (60%)	12 (100%)	0.001
Participants with ≥15 points (moderate to severe) [ (%)]	22 (54%)	2 (40%)	0 (0%)	0.001
Range in points	0–59	0–60	0–13
Number of times per year a person experiences ≥2 symptoms in the SNOT-20 together
Never	9 (24%)	2 (40%)	7 (58%)	<0.001
1-2 times	4 (11%)	1 (20%)	1 (8%)
3-4 times	1 (2%)	0 (%)	4 (33%)
≥7	24 (63.2%)	2 (40%)	0 (0%)
Question left blank	3 (7%)	0 (0%)	0 (0%)

Statistical tests used for comparison: ^#ANOVA and ’s exact test.